FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

esmo - Evidence for efficacy is based on the findings from the ROSELLA study

AI Summary: The FDA granted marketing authorization for relacorilant in combination with nab‑paclitaxel to treat platinum‑resistant epithelial ovarian, fallopian tube and primary peritoneal cancers. Regulators cited clinical benefit in a difficult‑to‑treat population, providing an additional therapeutic option for patients with limited choices and marking an important regulatory milestone.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 15 days

Datroway secures regulatory approvals in breast cancer across US and EU / 8 days

FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 20 days

FDA grants early access to experimental pancreatic cancer drug / 29 days

FDA flags misleading cancer drug claims tied to biotech billionaire / 2 months

FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 47 hrs

FDA to revisit Atara/Pierre Fabre cell therapy approval for rare lymphoma / 22 days